COVID 19 Tech

FDA authorizes booster doses for 12- to 15-year-olds, shortens interval for adults

A health worker administers a third dose of the Pfizer-BioNTech Covid-19 vaccine to an elderly resident at Ichilov medical center in Tel Aviv, Israel, on Monday, Aug. 2, 2021.

Enlarge / A health worker administers a third dose of the Pfizer-BioNTech Covid-19 vaccine to an elderly resident at Ichilov medical center in Tel Aviv, Israel, on Monday, Aug. 2, 2021. (credit: Getty | Bloomberg )

As the ultra-transmissible omicron coronavirus variant bears down on the US, the Food and Drug Administration on Monday announced a set of sweeping changes to the availability of Pfizer-BioNTech booster doses .

The regulator expanded access to 3rd doses by authorizing their use for kids 12 to 15 years old. The agency also shortened the interval at which adults and children 12 and up can get a booster after their second dose—moving the time from six months to only five months. Last, the FDA made third doses available to immunocompromised children ages 5 to 11 who may not mount a strong response from only the first two doses.

The FDA’s moves are motivated by omicron and backed by data through Israel, which has a booster program further along than that of the united states. In fact, Israeli officials on Monday began offering fourth doses (second booster doses) of the Pfizer-BioNTech vaccine to people ages 60 and over in an effort to sustain high levels associated with protection in the population. The omicron variant, which is currently powering a vertical rise in cases in the particular US, has been found in order to thwart protection from only 2 vaccine doses, but it can still be defeated with enhancer doses.

Read 9 remaining paragraphs | Comments